Involvement of the L-DOPA receptor GPR143 in acute and chronic actions of methylphenidate

J Pharmacol Sci. 2023 Jul;152(3):178-181. doi: 10.1016/j.jphs.2023.04.006. Epub 2023 Apr 28.

Abstract

Methylphenidate (MPH) and methamphetamine (METH) are the current treatments of choice for attention deficit/hyperactivity disorder. We previously reported that METH induces the release of dopamine (DA) and of the neurotransmitter candidate L-3,4-dihydroxyphenylalanine (L-DOPA). In contrast, we here found that MPH increased the DA release while it did not affect the L-DOPA release from the dorsolateral striatum. Nevertheless, MPH-induced hyperlocomotion was reduced in Gpr143 (L-DOPA receptor) gene-deficient (Gpr143-/y) mice. The rewarding effect and increased c-fos expression induced by MPH were also attenuated in Gpr143-/y mice. Together, these findings suggest that GPR143 is involved in the acute and chronic actions of MPH.

Keywords: GPR143; L-DOPA; Methylphenidate.

MeSH terms

  • Animals
  • Central Nervous System Stimulants* / pharmacology
  • Dopamine / metabolism
  • Levodopa / pharmacology
  • Methamphetamine* / pharmacology
  • Methylphenidate* / pharmacology
  • Mice
  • Receptors, Neurotransmitter

Substances

  • Methylphenidate
  • levodopa receptor
  • Levodopa
  • Receptors, Neurotransmitter
  • Dopamine
  • Methamphetamine
  • Central Nervous System Stimulants